Redeye expects continued positive momentum in Isofol shares in the run-up to the interim analysis of the Phase III AGENT trial. We see tremendous valuation upside if arfolitixorin demonstrates a significant benefit over standard of care in first-line metastatic colorectal cancer. The upcoming recommendation from the independent Data Safety Monitoring Board (DSMB) will provide an early verdict. While investors should be aware of the high-risk nature of the review, we see good reasons to be optimistic.
We are strengthened in our confidence in the arfolitixorin project following recent progress in business and clinical development and reiterate our base case of SEK 35 per share.
